S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
S&P 500   3,959.72 (-0.10%)
DOW   33,689.04 (-0.27%)
QQQ   284.30 (+0.16%)
AAPL   144.00 (+0.95%)
MSFT   246.92 (-0.19%)
META   116.71 (+1.20%)
GOOGL   93.38 (-0.35%)
AMZN   89.61 (-0.82%)
TSLA   181.14 (+4.44%)
NVDA   173.15 (+0.85%)
NIO   12.79 (-4.62%)
BABA   91.71 (-2.61%)
AMD   69.53 (-1.33%)
T   19.20 (+0.42%)
MU   55.50 (+0.54%)
CGC   2.92 (-5.50%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.89 (-2.97%)
PYPL   73.94 (-0.38%)
PFE   51.93 (+0.29%)
NFLX   323.82 (+4.37%)
NASDAQ:NOVN

Novan - NOVN Stock Forecast, Price & News

$1.29
+0.07 (+5.74%)
(As of 12/9/2022 02:58 PM ET)
Add
Compare
Today's Range
$1.23
$1.32
50-Day Range
$0.82
$1.87
52-Week Range
$0.79
$5.05
Volume
1,163 shs
Average Volume
309,085 shs
Market Capitalization
$27.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Novan MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,069.4% Upside
$14.50 Price Target
Short Interest
Healthy
2.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.67) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

507th out of 1,022 stocks

Pharmaceutical Preparations Industry

224th out of 499 stocks

NOVN stock logo

About Novan (NASDAQ:NOVN) Stock

Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Stock News Headlines

NOVN: EPI Revenue Trends Are Strong - Benzinga
Novan: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Company Calendar

Last Earnings
11/10/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NOVN
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.50
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+1,024.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-29,690,000.00
Net Margins
-263.58%
Pretax Margin
-263.58%

Debt

Sales & Book Value

Annual Sales
$2.96 million
Book Value
$0.97 per share

Miscellaneous

Free Float
20,856,000
Market Cap
$27.45 million
Optionable
Not Optionable
Beta
0.30

Key Executives

  • Ms. Paula Brown Stafford M.P.H. (Age 57)
    Pres, CEO & Chairwoman
    Comp: $1.01M
  • Mr. John M. Gay CPA (Age 46)
    CFO & Corp. Sec.
    Comp: $482.26k
  • Mr. Brian M. Johnson (Age 56)
    Chief Commercial Officer
    Comp: $443k
  • Mr. John A. Donofrio Jr. (Age 55)
    Exec. VP, COO & Pres of EPI Health
  • Mr. Andrew J. Novak
    VP of Accounting & Bus. Operations and Chief Accounting Officer
  • Dr. Carri Geer Ph.D.
    Sr. VP & CTO
  • Mr. Cole Ikkala
    Director of Investor Relations, Communications & Bus. Devel.
  • Mr. Stanley Hollenbach BS
    J.D., Sr. VP of R&D
  • Dr. Tomoko Maeda-Chubachi M.B.A.
    M.D., Ph.D., Chief Medical Officer













NOVN Stock - Frequently Asked Questions

Should I buy or sell Novan stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NOVN shares.
View NOVN analyst ratings
or view top-rated stocks.

What is Novan's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month target prices for Novan's shares. Their NOVN share price forecasts range from $12.00 to $17.00. On average, they predict the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 1,032.8% from the stock's current price.
View analysts price targets for NOVN
or view top-rated stocks among Wall Street analysts.

How have NOVN shares performed in 2022?

Novan's stock was trading at $4.17 at the beginning of 2022. Since then, NOVN stock has decreased by 69.3% and is now trading at $1.28.
View the best growth stocks for 2022 here
.

When is Novan's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our NOVN earnings forecast
.

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.08. The business earned $0.74 million during the quarter, compared to analysts' expectations of $0.74 million. Novan had a negative trailing twelve-month return on equity of 378.26% and a negative net margin of 263.58%. During the same period in the prior year, the firm posted ($0.60) earnings per share.

What other stocks do shareholders of Novan own?
When did Novan IPO?

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Who are Novan's major shareholders?

Novan's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (10.77%), Renaissance Technologies LLC (1.29%), Wealthsource Partners LLC (0.73%), B. Riley Wealth Advisors Inc. (0.41%), Citadel Advisors LLC (0.08%) and Forum Financial Management LP (0.07%). Insiders that own company stock include James L Bierman, John M Gay, John W Palmour and Paula B Stafford.
View institutional ownership trends
.

How do I buy shares of Novan?

Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $1.28.

How much money does Novan make?

Novan (NASDAQ:NOVN) has a market capitalization of $27.24 million and generates $2.96 million in revenue each year. The company earns $-29,690,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The official website for the company is www.novan.com. The company can be reached via phone at (919) 485-8080, via email at cikkala@novan.com, or via fax at 919-237-9212.

This page (NASDAQ:NOVN) was last updated on 12/9/2022 by MarketBeat.com Staff